Associated Papers
Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy.
Madi A et al.
European Journal of Cancer (oxford, England : 1990), 2018
Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach.
Boisdron-Celle M et al.
Seminars in Oncology, 2017
Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.
Frank TS et al.
Cancer Letters, 2015
Part 1: background, methodology, and clinical adoption of pharmacogenetics.
Deenen MJ et al.
The Oncologist, 2011
The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer.
Capitain O et al.
The Pharmacogenomics Journal, 2008
Predicting drug response and toxicity based on gene polymorphisms.
Robert J et al.
Critical Reviews in Oncology/hematology, 2005
Select a paper to view details